資源描述：
《瑞信-美股-制藥業(yè)-美國制藥業(yè)2018展望：宏觀背景利好-20171218-125頁》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、USPharmaceuticals2018Outlook:MacroBackdropFavorable,ContinuedInnovationKeytoUpside?LayingOutOurWishListforUSPharma:InconjunctionwithournotelayingoutourwishlistforDecember18,2017USPharmaforthenext12months,wepresenthereourthoughtsonwhatweseeassomeofthekeydriversofthegroupfor2018.Withconcer
2、nsarounddrugpricingmoderatedatleastforthetimebeing,themacrobackdropremainsfavorable.ThelikelypassageofU.S.corporatetaxreformshouldRESEARCHANALYSTShelptodriverepatriationoffundsfromoverseasandleadtoanincreaseinM&Aactivityinthespace,VamilDivan,MDboostingthegrowthoutlookforlargecapcompanies
3、andincreasinginvestorinterestincompaniesof(212)538-5394allcapsizesthatcouldbepotentialtargets.Additionalfundsfordividendgrowthandsharevamil.divan@credit-suisse.comrepurchasesshouldalsoboosttheoveralloutlookforthesectorfromaninvestorperspective.WeseeMichaelV.Morabito,Ph.D.theregulatoryenv
4、ironmentremaininggenerallyfavorableandprovidingmorerapidpathstomarket(212)325-7298forproductsthatbringrealinnovation,butdeliveringthatinnovationremainsparamountformichael.morabito@credit-suisse.comcompaniestocompeteinanincreasinglychallengingpayerenvironmentanddeliverupsidein2018.Barbara
5、Kotei(212)538-8119?JNJRemainsOurTopPick,WhileWeExpectMRKandAGNtoRebound:Onanindividualbarbara.kotei@credit-suisse.comcompanybasiswecontinuetoseeJNJasourTopPickinlargecap,drivenbyarobustpharmabusiness,includingassetssuchasDarzalex,ImbruvicaandXarelto,thatwethinkwillexceedcurrentDuaaMohame
6、dexpectations.MRKandAGNarealsoOutperform-ratedafterdisappointingperformanceduringthe(212)538-8127duaa.mohamed.2@credit-suisse.comlatterpartof2017providingattractiveentrypointsfornewinvestorsfor2018.ForMRK,weexpectpositivedataforKEYNOTE-189fromoneoftheinterimanalysespendingin2018,whileKEY
7、NOTE-042andKEYNOTE-407shouldalsoprovidepositivedatareadoutsin1Lnon-smallcelllungcancer.ForAGN,webelieveitiscriticalforthepipelinetodeliverpositivedata,mostnotablyfromtheoralCGRPsthatwillreadoutin1Q2018,tooffsetthepressurefromgenericcompetitionformultipleproducts.?Multiple
